Home Featured Page 140

Featured

Latest

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber;...

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

PT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch,...

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

PT348 – Steve DeAngelo – Cannabis and Psychedelics: Industry, Consciousness, Justice,...

HAVN Life Announces the close of the first tranche of its...

Bright Minds Biosciences Comments on Recent Trading Activity

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

1...139140141...291 Page 140 of 291

EDITOR PICKS

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

Pα+ Psychedelic Bulletin #202: Psychedelics Access ‘Within 12 Months’, RFK Jr. Says; Psychedelics in Washington; Lykos’ New CEO, CMO; New Zealand’s First Psilocybin Prescriber;...

Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results

PT349 – Brenna Gebauer – Slowing Down, The Ethics of Touch,...

Interview | Josh Ismin, Psylo

Opinions | The Psychedelic Community Takes Itself Too Seriously

Algernon Pharmaceuticals Announces Private Placement

Issues of Patient Safety and Ethical Violations in Psychedelic Therapy

Psychedelic Bulletin #115 – Mydecine Looks Set to Shutter; MindMed Gains...

PT348 – Steve DeAngelo – Cannabis and Psychedelics: Industry, Consciousness, Justice,...

HAVN Life Announces the close of the first tranche of its...

Bright Minds Biosciences Comments on Recent Trading Activity

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

EDITOR PICKS

Beyond the Endpoint: Industry Voices Reflect on Compass’ Phase 3 Readout

It’s Time to Push Back: Meta’s War on Psychedelic Voices

Victoria Litman – The Future of Psychedelic Regulation Is Local

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY